Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 6,076 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Active, not recruiting Phase 2 Interventional

A Study of Mosliciguat in PH-ILD

NCT06635850
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
Mosliciguat, Dry Powder Inhaler, Placebo
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 3 Interventional Results available

Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

NCT01499849
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 28, 2026, 9:25 PM EDT
Terminated Phase 3 Interventional Results available

Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects

NCT04084678
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Tucson, Arizona • Aurora, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exoskeletal Support in Stroke

NCT05996198
View directory record Official record
Conditions
Stroke
Interventions
Oculus Rift headset, Exoskeleton Device
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 3 Interventional Results available

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02493452
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
191
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 28, 2026, 9:25 PM EDT
Recruiting Phase 3 Interventional

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
IKT-001, Placebo
Drug
Lead sponsor
Inhibikase Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Scottsdale, Arizona • Beverly Hills, California • Santa Barbara, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

NCT02978326
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

NCT01324232
View directory record Official record
Conditions
Central Neuropathic Pain, Multiple Sclerosis
Interventions
AVP-923-45, AVP-923-30, AVP-923-20, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 28, 2026, 9:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Hyper-Arousal in Chronic Primary Insomnia

NCT02048878
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 2 Interventional Results available

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

NCT04001517
View directory record Official record
Conditions
Dementia With Lewy Bodies (DLB)
Interventions
Neflamapimod
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
55 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
La Jolla, California • Santa Monica, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 28, 2026, 9:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound

NCT04756193
View directory record Official record
Conditions
Covid19, Echocardiography, Ultrasound
Interventions
Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound
Diagnostic Test
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of ARRY-371797 in Healthy Subjects

NCT00790049
View directory record Official record
Conditions
Healthy
Interventions
ARRY-371797, p38 inhibitor; oral, Placebo; oral
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 1 Interventional

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

NCT00626249
View directory record Official record
Conditions
Mild Nephropathy, Moderate Nephropathy, Diabetes Mellitus
Interventions
Technosphere Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Minneapolis, Minnesota • Omaha, Nebraska • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 3 Interventional Results available

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

NCT00605215
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Laquinimod, Placebo, Avonex®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy

NCT02223182
View directory record Official record
Conditions
Food Allergy
Interventions
Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg, Viaskin Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
2 Years to 17 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 28, 2026, 9:25 PM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 28, 2026, 9:25 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects

NCT07678346
View directory record Official record
Conditions
Systemic Inflammation (hsCRP), Healthy Aging, Vitality, Healthy Adult Participants
Interventions
Apple Extract, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraland USA, Inc.
Industry
Eligibility
45 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 28, 2026, 9:25 PM EDT
Recruiting Phase 2 Interventional

A Trial of CRD-4730 in HFrEF

NCT07750873
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
CRD-4730, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Pasadena, California • Bloomfield Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use

NCT05345951
View directory record Official record
Conditions
Underage Drinking, Cannabis Use, Drinking, Teen, Drinking, College, College Drinking, Teen Drinking
Interventions
e-PBI
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 19 Years
Enrollment
1,980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 28, 2026, 9:25 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety of HRX215 in Patients After Minor and Major Liver Resection

NCT06638502
View directory record Official record
Conditions
Liver Resection, Colorectal Carcinoma Liver Metastases
Interventions
HRX215 capsules, Placebo capsules
Drug
Lead sponsor
HepaRegeniX GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 9:25 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II

NCT01451723
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Polyphenon E, Placebo
Drug · Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects

NCT02313103
View directory record Official record
Conditions
Renally Impaired Subjects
Interventions
lofexidine HCl
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 28, 2026, 9:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dapagliflozin In Alzheimer's Disease

NCT03801642
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
Jeff Burns, MD
Other
Eligibility
50 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 28, 2026, 9:25 PM EDT